Moderna reports third quarter 2022 financial results and provides business updates

Third quarter 2022 revenues of $3.4 billion; gaap net income of $1.0 billion and gaap diluted eps of $2.53 revenue from advance purchase agreements for anticipated delivery in 2022 expected to be $18 to $19 billion, following delay of certain deliveries into 2023 due to short-term supply constraints primary efficacy analysis from phase 2 study for personalized cancer vaccine program (mrna-4157/v940) expected in 4q22 phase 3 rsv vaccine efficacy data could read out this winter phase 3 flu vaccine immunogenicity data expected in 1q23 completed $3 billion share repurchase plan announced in february 2022; commenced august 2022 $3 billion share repurchase program cambridge, ma / accesswire / november 3, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today reported financial results and provided business updates for the third quarter of fiscal year 2022. "today's earnings continue to show strong corporate momentum.
MRNA Ratings Summary
MRNA Quant Ranking